乳腺癌基因治疗的研究动态与展望  

Current status of gene therapy for breast cancer

作　　者：欧周罗[1] OU Zhouluo(Fudan University Shanghai Cancer Center,Breast Cancer Institute of Fudan University,Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属肿瘤医院,复旦大学乳腺癌研究所,复旦大学上海医学院肿瘤学系,上海200032

出　　处：《延安大学学报（医学科学版）》2022年第4期1-5,共5页Journal of Yan'an University:Medical Science Edition

摘　　要：乳腺癌易感基因BRCA1、BRCA2的突变分析及MammaPrint、Oncotype DX等多基因检测,HER2及PD-1、PD-L1靶向治疗与化学治疗等传统治疗手段的联合应用,针对表观遗传学改变的新药自主研发,基于多组学图谱的三阴性乳腺癌分子分型等,这些成果反映了近年来中国乳腺癌基因治疗研究的历史性进步,极大地促进了临床诊断和治疗水平的提高,为征服乳腺癌这一全球最常见恶性肿瘤带来了新的希望。Identification of breast cancer susceptibility gene BRCA1,BRCA2 mutation,multi-gene assay with MammaPrint,Oncotype DX,combination of targeted therapy against HER2,PD-1,PD-L1 and so on and traditional strategies including chemotherapy,independent research and development of epigenetic drugs and a novel classification of triple negative breast cancer reflected the historic progress of gene therapy for breast cancer in China and greatly improved the clinical diagnosis and treatment of breast cancer. It also brings hope to conquer breast cancer,the most common malignant tumor around the world,in the near future.

关 键 词：乳腺癌 基因治疗 癌基因 抑癌基因 分子分型 

分 类 号：R737.9[医药卫生—肿瘤]